eÃcacy in such severe dyslipidaemia. Subsequently we performed 10 LDL-A sessions to lower cholesterol concentration [1] , whilst tapering the prednisone dose A 43 year-old-man presented in August 1992 with from 15 mg to 9 mg per day. The other drugs prescribed nephrotic syndrome. For the previous 3 months he were sulphasalazine 2 g/day until July 1995, and frusehad been treated for ankylosing spondylitis with mide, which was given at a dose of 500 mg/day until sulphasalazine 2 g per day. Percutaneous renal biopsy September 1995; this treatment was then progressively showed normal glomeruli without mesangial hypercelreduced and stopped; omeprazole 20 mg/day, cizapride lularity. The nephrotic syndrome was steroid-20 mg/day, nadroparine 0.6 ml b.i.d. and fenofibrate dependent with a high threshold ( 40 mg prednisone 67 mg/day from October 1995. per day). Between 1992 and 1995 the patient experi-LDL apheresis [1 ] was performed using haemofilter enced severe relapses despite continuous steroid treatSorin BT 900 with a surface of 1.10 m2 as the plasma ment (with serum albumin falling to 12 g/l ). A second separator and a dextran sulphate cellulose column renal biopsy performed in September 1993 showed (Liposorber LA-40, Kaneka, Japan) as the LDL minimal-change disease. Successive concurrent therapy absorber. A double-lumen central vascular access was with cyclosporin A, chlorambucil, and quinolones used and 55 ml/kg of plasma processed at each session. failed to improve the condition.
The duration of each procedure was about 2 h. We In April 1995, a massive relapse of the nephrotic performed 10 LDL-A in a period of 9 weeks. During syndrome was associated with deterioration of renal the LDL-A period, serum cholesterol decreased from function (plasma creatinine 180 mmol/l ). A third renal 28 mmol/l to 9.5 mmol/l and serum triglycerides from biopsy was performed and showed minimal changes 20 mmol/l to 3.5 mmol/l ( Figure 1 ). Proteinuria with global sclerosis of 3/9 glomeruli. Segmental glomdecreased to 1.26 g/day after the last LDL-A session, erular hyalinosis was not observed. There were some in parallel with the reduction in serum cholesterol r= focal areas of fibrosis with tubular atrophy, but no 0.9 ( Figure 2 ). From session 4, serum albumin concencellular infiltration. Clinical deterioration and progrestrations rose progressively to reach the normal range sion of biochemical changes occurred despite a new after session 6. Renal function improved progressively therapeutic regimen: two pulses of 500 mg methylprednisolone followed by prednisone 50 mg per day, and then polyvalent immunoglobulins. The patient Potential role of sulphasalazine in the nephrotic syndrome The patient had been treated for ankylosing spondylitis since the age of 18. Sulphasalazine therapy was started 3 months before the onset of the nephrotic syndrome and stopped 2 months before signs of improvement were first seen. This chronology suggests a potential role of sulphasalazine in the development of the nephrotic syndrome. There have been few reports of nephrotoxicity associated with sulphasalazine in patients being treated for ulcerative colitis [2, 3] , and only one case of nephrotic syndrome has been reported [3] .
In the patient reported here, three renal biopsies failed to demonstrate inflammatory interstitial lesions suggestive of drug-related nephrotic syndrome.
Potential beneficial eÂects of LDL-apheresis on the outcome of the nephrotic syndrome
We found a strong correlation (r=0.9) between the decrease of serum cholesterol levels and the reduction of proteinuria during LDL-A. Renal function improved during the treatment period. Recent investigations have provided evidence for the adverse renal eÂects of hyperlipidemia [4, 5] . Lipoproteins can bind to polyanionic glycosaminoglycans in the mesangial matrix and glomerular basement membrane and may alter the permeability of the latter by neutralizing fixed negative charges in the filtration barrier [6 ] . Correction of serum lipid levels may therefore have a beneficial eÂect on renal function. The benefits of LDL-A on renal function and proteinuria in this case are consistent with previous reports. Hattori et al. [7] reported the case of a 15-year-old boy with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis. A slight improvement in renal function, hypercholesterolaemia, proteinuria and hypoalbuminaemia following treatment with pravastatin and LDL-A was observed. Muso et al.
[8 ] performed LDL-A treatment in nine cases of steroid-resistant nephrotic syndrome and observed a 40-50% improvement in Fig. 2 . Cholesterol vs proteinuria proteinuria and hypoalbuminaemia in five patients. However, six of the nine cases received concurrent steroid therapy or immunosuppressants and LDL-A. and serum creatinine was 150 mmol/l after session 7.
The removal by dextran sulphate adsorption of a Six months after the last LDL-A session, proteinuria circulating factor responsible for the nephrotic synwas 0.01 g/day, serum creatinine 135 mmol/l, serum drome is another hypothesis to explain the benefits of albumin 44 g/l, cholesterol 5.16 mmol/l, and triglycer-LDL-A. LDL-A removes not only LDL and VLDL ides 2.6 mmol/l. Two adverse events occurred during but also immunoglobulins [9 ] . Cases of mild and the LDL-A period: priapism after the 3rd LDL-A transitory improvement have been reported after session (LDL-A treatment was therefore interrupted plasmapheresis or protein adsorption column [10, 11] . for 3 weeks) and a Staphylococcus epidermidis septi-However, there are no reports of complete remission caemia after urological explorations. after these treatments. These apheresis techniques do not use dextran sulphate adsorption. Further advantages of LDL-A over other apheresis techniques would Discussion be the absence of exposure to exogenous blood products and the hypolipidaemic eÂect of the procedure. Two factors could have favoured the remission of nephrotic syndrome in this patient: the withdrawal of Acknowledgements. The authors thank Pr. A. Baumelou, CHU Pitié-Salpêtriére, Paris, for assistance in preparing the manuscript. sulphasalazine and the LDL-A treatment.
